ScaleReady

Executive Summary

ScaleReady is a Cambridge-based biotechnology company addressing the critical manufacturing bottleneck in cell and gene therapy (CGT) through its proprietary G-Rex platform. The G-Rex system enables linear scalability from research through commercial production, reducing process variables and costs while maintaining high cell quality. Founded in 2018, ScaleReady aims to make CGT business viable by simplifying complex manufacturing workflows. Currently at the pre-clinical stage, the company operates as a private entity with no disclosed funding or valuation, yet its platform technology has the potential to become an industry standard for CGT production. The company's focus on reducing cost of goods and improving scalability aligns well with the growing demand for affordable, large-scale cell therapies. While still early-stage, ScaleReady's technology addresses a key pain point in the industry, positioning it for potential partnerships or licensing deals as it advances toward clinical validation.

Upcoming Catalysts (preview)

• Q1 2027Series A or B Funding Round70% success
• Q4 2026Strategic Partnership with CGT Developer60% success
• Q3 2026Publication of G-Rex Performance Data in Peer-Reviewed Journal80% success